Siemens Healthineers Begins Carve-Out of Diagnostics Unit as Olyrian Diagnostics

Siemens Healthineers has started carving out its in vitro diagnostics business, a step toward a standalone company that will operate under the name Olyrian Diagnostics, the company said. The parent firm also plans to change its own name to Healthineers. Both transitions will run in parallel, and the Olyrian name will be introduced in stages. The company expects the separation to be completed by mid-2028.

The diagnostics business will remain part of Siemens Healthineers during the transition. The company said there is no change to products and services, contracts, service levels or customer points of contact as of the announcement. It said it will issue updates as the carve-out progresses and will communicate any future changes directly to customers.

A Dedicated Identity for Diagnostics

The company said a dedicated name and brand will give the diagnostics business a distinct market presence as one of the largest stand-alone diagnostics-focused companies. Olyrian will supply diagnostic solutions for laboratory and point-of-care testing, covering the journey from patient draw to population health. The company said its stated purpose reflects a focus on in vitro diagnostics and a commitment to combine intelligent technology with the work of the people who make, interpret and act on diagnostic information.

Sharon Bracken, who leads diagnostics for Siemens Healthineers, said the laboratory sits at the heart of care, where teams provide the critical answers patients need, and described Olyrian Diagnostics as the way the business will define its next chapter. The comments were issued in a company release announcing the carve-out.

Siemens Healthineers built the in vitro diagnostics business by acquiring three companies in 2006 and 2007, whose histories date back to as early as 1884, according to the company. The unit now manufactures more than 16 billion tests annually across an assay portfolio that the company says addresses nearly every major disease area. Its milestones include the first urine test strip for diabetes and what the company describes as the industry's first automated, integrated clinical chemistry and immunoassay analyzer. The current portfolio includes laboratory automation, informatics and point-of-care testing solutions.

What It Means for Laboratory Workers

For people working in laboratory diagnostics, the separation creates a larger, specialized organization focused only on testing, from routine clinical chemistry to point-of-care devices used closer to patients. The company's emphasis on automation and informatics suggests that laboratory staff will keep working alongside systems that handle sample tracking, result reporting and data analysis, skills that laboratory medicine programs increasingly cover.

The transition also has implications for the commercial and service side of the business. Sales teams, field service engineers and customer support staff currently work within a broader health technology company that also sells imaging and other equipment. Once Olyrian operates independently, those roles will sit inside an organization whose entire business is diagnostics, which the company argues will sharpen its market focus.

What to Watch Next

The company has not announced changes to staffing levels, facility locations or contracts, and it said products and services remain unchanged for now. The main milestones to track are the staged rollout of the Olyrian brand and the completion of the separation by mid-2028, along with any updates the company provides to customers as the process advances.